nodes	percent_of_prediction	percent_of_DWPC	metapath
Cysteamine—SST—hepatic artery—liver cancer	0.206	0.34	CbGeAlD
Cysteamine—SST—portal vein—liver cancer	0.179	0.295	CbGeAlD
Cysteamine—MPO—superior mesenteric artery—liver cancer	0.158	0.261	CbGeAlD
Cysteamine—SST—gall bladder—liver cancer	0.0307	0.0507	CbGeAlD
Cysteamine—SST—embryo—liver cancer	0.0195	0.0322	CbGeAlD
Cysteamine—NPY2R—Circadian rythm related genes—SIX3—liver cancer	0.0109	0.0519	CbGpPWpGaD
Cysteamine—NPY2R—Peptide GPCRs—CCR4—liver cancer	0.00967	0.046	CbGpPWpGaD
Cysteamine—Nephrotic syndrome—Sorafenib—liver cancer	0.00939	0.051	CcSEcCtD
Cysteamine—SST—liver—liver cancer	0.00901	0.0149	CbGeAlD
Cysteamine—MPO—Selenium Micronutrient Network—EPT1—liver cancer	0.00702	0.0334	CbGpPWpGaD
Cysteamine—Tubulointerstitial nephritis—Sorafenib—liver cancer	0.00592	0.0322	CcSEcCtD
Cysteamine—MPO—IL23-mediated signaling events—STAT4—liver cancer	0.00538	0.0256	CbGpPWpGaD
Cysteamine—Bone disorder—Sorafenib—liver cancer	0.00502	0.0273	CcSEcCtD
Cysteamine—MPO—IL23-mediated signaling events—IL12B—liver cancer	0.00493	0.0234	CbGpPWpGaD
Cysteamine—SST—Peptide ligand-binding receptors—CCR4—liver cancer	0.00475	0.0226	CbGpPWpGaD
Cysteamine—NPY2R—Peptide ligand-binding receptors—CCR4—liver cancer	0.00455	0.0216	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—AHR—liver cancer	0.00415	0.0197	CbGpPWpGaD
Cysteamine—SST—G alpha (i) signalling events—CCR4—liver cancer	0.004	0.019	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—GPX3—liver cancer	0.0039	0.0186	CbGpPWpGaD
Cysteamine—NPY2R—G alpha (i) signalling events—CCR4—liver cancer	0.00384	0.0182	CbGpPWpGaD
Cysteamine—Hepatic function abnormal—Sorafenib—liver cancer	0.00377	0.0205	CcSEcCtD
Cysteamine—MPO—liver—liver cancer	0.00363	0.00599	CbGeAlD
Cysteamine—NPY2R—GPCRs, Class A Rhodopsin-like—CCR4—liver cancer	0.00356	0.0169	CbGpPWpGaD
Cysteamine—Pain in extremity—Sorafenib—liver cancer	0.00329	0.0179	CcSEcCtD
Cysteamine—SST—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.00318	0.0151	CbGpPWpGaD
Cysteamine—Mood swings—Sorafenib—liver cancer	0.00312	0.017	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—GPX3—liver cancer	0.0031	0.0147	CbGpPWpGaD
Cysteamine—Dehydration—Sorafenib—liver cancer	0.00306	0.0167	CcSEcCtD
Cysteamine—NPY2R—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.00305	0.0145	CbGpPWpGaD
Cysteamine—Optic neuritis—Epirubicin—liver cancer	0.00273	0.0148	CcSEcCtD
Cysteamine—Optic neuritis—Doxorubicin—liver cancer	0.00252	0.0137	CcSEcCtD
Cysteamine—Renal failure—Sorafenib—liver cancer	0.00249	0.0136	CcSEcCtD
Cysteamine—Redness—Epirubicin—liver cancer	0.00248	0.0135	CcSEcCtD
Cysteamine—MPO—Vitamin B12 Metabolism—MTHFR—liver cancer	0.00246	0.0117	CbGpPWpGaD
Cysteamine—SST—GPCR ligand binding—CCR4—liver cancer	0.00242	0.0115	CbGpPWpGaD
Cysteamine—NPY2R—GPCR ligand binding—CCR4—liver cancer	0.00232	0.011	CbGpPWpGaD
Cysteamine—Redness—Doxorubicin—liver cancer	0.0023	0.0125	CcSEcCtD
Cysteamine—Urinary tract disorder—Sorafenib—liver cancer	0.00225	0.0122	CcSEcCtD
Cysteamine—Connective tissue disorder—Sorafenib—liver cancer	0.00224	0.0122	CcSEcCtD
Cysteamine—Urethral disorder—Sorafenib—liver cancer	0.00223	0.0121	CcSEcCtD
Cysteamine—Scotoma—Epirubicin—liver cancer	0.00221	0.012	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—GGT1—liver cancer	0.00218	0.0104	CbGpPWpGaD
Cysteamine—MPO—Vitamin B12 Metabolism—F2—liver cancer	0.00216	0.0103	CbGpPWpGaD
Cysteamine—Immune system disorder—Sorafenib—liver cancer	0.00206	0.0112	CcSEcCtD
Cysteamine—Scotoma—Doxorubicin—liver cancer	0.00204	0.0111	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—MTHFR—liver cancer	0.002	0.00952	CbGpPWpGaD
Cysteamine—Mental disorder—Sorafenib—liver cancer	0.002	0.0109	CcSEcCtD
Cysteamine—Malnutrition—Sorafenib—liver cancer	0.00198	0.0108	CcSEcCtD
Cysteamine—Erythema—Sorafenib—liver cancer	0.00198	0.0108	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—PPARA—liver cancer	0.00194	0.00923	CbGpPWpGaD
Cysteamine—SST—Peptide ligand-binding receptors—F2—liver cancer	0.0019	0.00901	CbGpPWpGaD
Cysteamine—MPO—IL23-mediated signaling events—IL2—liver cancer	0.00188	0.00895	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—GSTM1—liver cancer	0.00187	0.00889	CbGpPWpGaD
Cysteamine—Bone disorder—Epirubicin—liver cancer	0.00186	0.0101	CcSEcCtD
Cysteamine—SST—Signaling Pathways—CHN2—liver cancer	0.00185	0.00877	CbGpPWpGaD
Cysteamine—Anaemia—Sorafenib—liver cancer	0.00183	0.00997	CcSEcCtD
Cysteamine—Thinking abnormal—Epirubicin—liver cancer	0.00183	0.00996	CcSEcCtD
Cysteamine—NPY2R—Peptide ligand-binding receptors—F2—liver cancer	0.00182	0.00864	CbGpPWpGaD
Cysteamine—MPO—Vitamin B12 Metabolism—SERPINE1—liver cancer	0.0018	0.00855	CbGpPWpGaD
Cysteamine—MPO—Vitamin B12 Metabolism—ALB—liver cancer	0.0018	0.00854	CbGpPWpGaD
Cysteamine—Leukopenia—Sorafenib—liver cancer	0.00178	0.00965	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—CHN2—liver cancer	0.00177	0.00841	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—F2—liver cancer	0.00176	0.00836	CbGpPWpGaD
Cysteamine—Bone disorder—Doxorubicin—liver cancer	0.00172	0.00934	CcSEcCtD
Cysteamine—Hypertension—Sorafenib—liver cancer	0.00171	0.00931	CcSEcCtD
Cysteamine—Thinking abnormal—Doxorubicin—liver cancer	0.00169	0.00922	CcSEcCtD
Cysteamine—SST—Signaling Pathways—IFT88—liver cancer	0.00169	0.00802	CbGpPWpGaD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00168	0.00912	CcSEcCtD
Cysteamine—Phosphatase alkaline increased—Epirubicin—liver cancer	0.00168	0.00912	CcSEcCtD
Cysteamine—Anaphylactic shock—Sorafenib—liver cancer	0.00162	0.0088	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—IFT88—liver cancer	0.00162	0.00769	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—PPARG—liver cancer	0.00161	0.00763	CbGpPWpGaD
Cysteamine—MPO—Selenium Micronutrient Network—MTHFR—liver cancer	0.00159	0.00757	CbGpPWpGaD
Cysteamine—Nervous system disorder—Sorafenib—liver cancer	0.00159	0.00863	CcSEcCtD
Cysteamine—MPO—IL23-mediated signaling events—STAT3—liver cancer	0.00158	0.00753	CbGpPWpGaD
Cysteamine—Skin disorder—Sorafenib—liver cancer	0.00157	0.00855	CcSEcCtD
Cysteamine—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.00155	0.00844	CcSEcCtD
Cysteamine—Anorexia—Sorafenib—liver cancer	0.00154	0.00839	CcSEcCtD
Cysteamine—SST—SIDS Susceptibility Pathways—CASP3—liver cancer	0.0015	0.00712	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—SERPINE1—liver cancer	0.00146	0.00696	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—ALB—liver cancer	0.00146	0.00694	CbGpPWpGaD
Cysteamine—Mental disability—Epirubicin—liver cancer	0.00146	0.00791	CcSEcCtD
Cysteamine—SST—SIDS Susceptibility Pathways—JUN—liver cancer	0.00145	0.00691	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—SERPINE1—liver cancer	0.00145	0.00688	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—CTNNB1—liver cancer	0.00144	0.00686	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—TRIO—liver cancer	0.00143	0.00679	CbGpPWpGaD
Cysteamine—Dyspepsia—Sorafenib—liver cancer	0.00142	0.00775	CcSEcCtD
Cysteamine—Decreased appetite—Sorafenib—liver cancer	0.00141	0.00765	CcSEcCtD
Cysteamine—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.0014	0.00761	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—F2—liver cancer	0.0014	0.00664	CbGpPWpGaD
Cysteamine—Gastrointestinal disorder—Sorafenib—liver cancer	0.0014	0.0076	CcSEcCtD
Cysteamine—Fatigue—Sorafenib—liver cancer	0.0014	0.00759	CcSEcCtD
Cysteamine—Hepatic function abnormal—Epirubicin—liver cancer	0.00139	0.00757	CcSEcCtD
Cysteamine—Constipation—Sorafenib—liver cancer	0.00138	0.00753	CcSEcCtD
Cysteamine—MPO—IL23-mediated signaling events—TNF—liver cancer	0.00137	0.00652	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—TRIO—liver cancer	0.00137	0.00651	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—CCR4—liver cancer	0.00137	0.00651	CbGpPWpGaD
Cysteamine—Eye pain—Epirubicin—liver cancer	0.00135	0.00733	CcSEcCtD
Cysteamine—Mental disability—Doxorubicin—liver cancer	0.00135	0.00732	CcSEcCtD
Cysteamine—Gastrointestinal pain—Sorafenib—liver cancer	0.00132	0.0072	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—CCR4—liver cancer	0.00131	0.00624	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—TRIO—liver cancer	0.0013	0.00617	CbGpPWpGaD
Cysteamine—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00129	0.00704	CcSEcCtD
Cysteamine—Hepatic function abnormal—Doxorubicin—liver cancer	0.00129	0.00701	CcSEcCtD
Cysteamine—Urticaria—Sorafenib—liver cancer	0.00129	0.00699	CcSEcCtD
Cysteamine—Body temperature increased—Sorafenib—liver cancer	0.00128	0.00696	CcSEcCtD
Cysteamine—Abdominal pain—Sorafenib—liver cancer	0.00128	0.00696	CcSEcCtD
Cysteamine—SST—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.00127	0.00605	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—VEGFA—liver cancer	0.00127	0.00604	CbGpPWpGaD
Cysteamine—MPO—IL23-mediated signaling events—PIK3CA—liver cancer	0.00125	0.00594	CbGpPWpGaD
Cysteamine—Eye pain—Doxorubicin—liver cancer	0.00125	0.00678	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—CCR4—liver cancer	0.00124	0.00591	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—TRIO—liver cancer	0.00124	0.00591	CbGpPWpGaD
Cysteamine—Lethargy—Epirubicin—liver cancer	0.00124	0.00675	CcSEcCtD
Cysteamine—NPY2R—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.00122	0.0058	CbGpPWpGaD
Cysteamine—Pain in extremity—Epirubicin—liver cancer	0.00122	0.00662	CcSEcCtD
Cysteamine—Affect lability—Epirubicin—liver cancer	0.0012	0.00651	CcSEcCtD
Cysteamine—Hypersensitivity—Sorafenib—liver cancer	0.00119	0.00649	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—CCR4—liver cancer	0.00119	0.00567	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—IL2—liver cancer	0.00118	0.00563	CbGpPWpGaD
Cysteamine—MPO—Selenium Micronutrient Network—SERPINE1—liver cancer	0.00116	0.00553	CbGpPWpGaD
Cysteamine—Asthenia—Sorafenib—liver cancer	0.00116	0.00632	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—ALB—liver cancer	0.00116	0.00552	CbGpPWpGaD
Cysteamine—Mood swings—Epirubicin—liver cancer	0.00115	0.00627	CcSEcCtD
Cysteamine—Lethargy—Doxorubicin—liver cancer	0.00115	0.00625	CcSEcCtD
Cysteamine—Ataxia—Epirubicin—liver cancer	0.00114	0.00622	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—JUN—liver cancer	0.00114	0.00541	CbGpPWpGaD
Cysteamine—Dehydration—Epirubicin—liver cancer	0.00113	0.00616	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CDKN2A—liver cancer	0.00113	0.00536	CbGpPWpGaD
Cysteamine—Pain in extremity—Doxorubicin—liver cancer	0.00113	0.00612	CcSEcCtD
Cysteamine—Liver function test abnormal—Epirubicin—liver cancer	0.00112	0.00611	CcSEcCtD
Cysteamine—Affect lability—Doxorubicin—liver cancer	0.00111	0.00603	CcSEcCtD
Cysteamine—Diarrhoea—Sorafenib—liver cancer	0.00111	0.00602	CcSEcCtD
Cysteamine—MPO—IL23-mediated signaling events—IL6—liver cancer	0.00111	0.00526	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—TNF—liver cancer	0.00109	0.00518	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—MAPK8—liver cancer	0.00108	0.00512	CbGpPWpGaD
Cysteamine—Dizziness—Sorafenib—liver cancer	0.00107	0.00582	CcSEcCtD
Cysteamine—Mood swings—Doxorubicin—liver cancer	0.00107	0.0058	CcSEcCtD
Cysteamine—MPO—Vitamin B12 Metabolism—TNF—liver cancer	0.00106	0.00504	CbGpPWpGaD
Cysteamine—Ataxia—Doxorubicin—liver cancer	0.00106	0.00576	CcSEcCtD
Cysteamine—Dehydration—Doxorubicin—liver cancer	0.00105	0.0057	CcSEcCtD
Cysteamine—Liver function test abnormal—Doxorubicin—liver cancer	0.00104	0.00565	CcSEcCtD
Cysteamine—SST—Signaling Pathways—SHC3—liver cancer	0.00103	0.00492	CbGpPWpGaD
Cysteamine—Vomiting—Sorafenib—liver cancer	0.00103	0.0056	CcSEcCtD
Cysteamine—Rash—Sorafenib—liver cancer	0.00102	0.00555	CcSEcCtD
Cysteamine—Dermatitis—Sorafenib—liver cancer	0.00102	0.00554	CcSEcCtD
Cysteamine—Headache—Sorafenib—liver cancer	0.00101	0.00551	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CDKN1B—liver cancer	0.000998	0.00474	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—SHC3—liver cancer	0.000992	0.00471	CbGpPWpGaD
Cysteamine—SST—GPCR ligand binding—F2—liver cancer	0.000969	0.0046	CbGpPWpGaD
Cysteamine—Nausea—Sorafenib—liver cancer	0.000961	0.00523	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CCND1—liver cancer	0.000952	0.00453	CbGpPWpGaD
Cysteamine—NPY2R—GPCR ligand binding—F2—liver cancer	0.000929	0.00441	CbGpPWpGaD
Cysteamine—Renal failure—Epirubicin—liver cancer	0.000922	0.00501	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—CDKN1A—liver cancer	0.000921	0.00438	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—IL6—liver cancer	0.000879	0.00418	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—TNF—liver cancer	0.000863	0.0041	CbGpPWpGaD
Cysteamine—MPO—Vitamin B12 Metabolism—IL6—liver cancer	0.000856	0.00407	CbGpPWpGaD
Cysteamine—Renal failure—Doxorubicin—liver cancer	0.000853	0.00464	CcSEcCtD
Cysteamine—Urinary tract disorder—Epirubicin—liver cancer	0.000832	0.00452	CcSEcCtD
Cysteamine—Connective tissue disorder—Epirubicin—liver cancer	0.000827	0.0045	CcSEcCtD
Cysteamine—Urethral disorder—Epirubicin—liver cancer	0.000825	0.00449	CcSEcCtD
Cysteamine—SST—Signaling Pathways—FST—liver cancer	0.000803	0.00382	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—PRKCE—liver cancer	0.000789	0.00375	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—FST—liver cancer	0.00077	0.00366	CbGpPWpGaD
Cysteamine—Urinary tract disorder—Doxorubicin—liver cancer	0.000769	0.00418	CcSEcCtD
Cysteamine—SST—Signaling Pathways—TRIO—liver cancer	0.000766	0.00364	CbGpPWpGaD
Cysteamine—Connective tissue disorder—Doxorubicin—liver cancer	0.000766	0.00416	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—MYC—liver cancer	0.000764	0.00363	CbGpPWpGaD
Cysteamine—Urethral disorder—Doxorubicin—liver cancer	0.000764	0.00415	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—TP53—liver cancer	0.000761	0.00362	CbGpPWpGaD
Cysteamine—Immune system disorder—Epirubicin—liver cancer	0.000761	0.00414	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—PRKCE—liver cancer	0.000756	0.00359	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—TP53—liver cancer	0.000752	0.00357	CbGpPWpGaD
Cysteamine—Mental disorder—Epirubicin—liver cancer	0.000738	0.00401	CcSEcCtD
Cysteamine—SST—Signaling Pathways—CCR4—liver cancer	0.000735	0.00349	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TRIO—liver cancer	0.000735	0.00349	CbGpPWpGaD
Cysteamine—Erythema—Epirubicin—liver cancer	0.000733	0.00399	CcSEcCtD
Cysteamine—Malnutrition—Epirubicin—liver cancer	0.000733	0.00399	CcSEcCtD
Cysteamine—Tension—Epirubicin—liver cancer	0.000719	0.00391	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—PRKCE—liver cancer	0.000716	0.0034	CbGpPWpGaD
Cysteamine—Nervousness—Epirubicin—liver cancer	0.000712	0.00387	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—KRAS—liver cancer	0.000706	0.00335	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CCR4—liver cancer	0.000704	0.00335	CbGpPWpGaD
Cysteamine—Immune system disorder—Doxorubicin—liver cancer	0.000704	0.00383	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—CSF2—liver cancer	0.000698	0.00332	CbGpPWpGaD
Cysteamine—MPO—Folate Metabolism—IL6—liver cancer	0.000696	0.00331	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—IL6—liver cancer	0.000688	0.00327	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—PRKCE—liver cancer	0.000687	0.00326	CbGpPWpGaD
Cysteamine—MPO—Selenium Micronutrient Network—TNF—liver cancer	0.000686	0.00326	CbGpPWpGaD
Cysteamine—Mental disorder—Doxorubicin—liver cancer	0.000683	0.00371	CcSEcCtD
Cysteamine—Erythema—Doxorubicin—liver cancer	0.000678	0.00369	CcSEcCtD
Cysteamine—Malnutrition—Doxorubicin—liver cancer	0.000678	0.00369	CcSEcCtD
Cysteamine—Anaemia—Epirubicin—liver cancer	0.000677	0.00368	CcSEcCtD
Cysteamine—Agitation—Epirubicin—liver cancer	0.000674	0.00366	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—CSF2—liver cancer	0.000669	0.00318	CbGpPWpGaD
Cysteamine—Tension—Doxorubicin—liver cancer	0.000666	0.00362	CcSEcCtD
Cysteamine—Nervousness—Doxorubicin—liver cancer	0.000659	0.00358	CcSEcCtD
Cysteamine—Leukopenia—Epirubicin—liver cancer	0.000656	0.00357	CcSEcCtD
Cysteamine—Convulsion—Epirubicin—liver cancer	0.000635	0.00345	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—CSF2—liver cancer	0.000634	0.00301	CbGpPWpGaD
Cysteamine—Hypertension—Epirubicin—liver cancer	0.000633	0.00344	CcSEcCtD
Cysteamine—Anaemia—Doxorubicin—liver cancer	0.000627	0.00341	CcSEcCtD
Cysteamine—Agitation—Doxorubicin—liver cancer	0.000623	0.00339	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00062	0.00337	CcSEcCtD
Cysteamine—Discomfort—Epirubicin—liver cancer	0.000617	0.00335	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—CSF2—liver cancer	0.000607	0.00289	CbGpPWpGaD
Cysteamine—Leukopenia—Doxorubicin—liver cancer	0.000607	0.0033	CcSEcCtD
Cysteamine—Confusional state—Epirubicin—liver cancer	0.000603	0.00328	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—HRAS—liver cancer	0.0006	0.00285	CbGpPWpGaD
Cysteamine—Anaphylactic shock—Epirubicin—liver cancer	0.000598	0.00325	CcSEcCtD
Cysteamine—Convulsion—Doxorubicin—liver cancer	0.000588	0.0032	CcSEcCtD
Cysteamine—Nervous system disorder—Epirubicin—liver cancer	0.000587	0.00319	CcSEcCtD
Cysteamine—Hypertension—Doxorubicin—liver cancer	0.000586	0.00318	CcSEcCtD
Cysteamine—Skin disorder—Epirubicin—liver cancer	0.000581	0.00316	CcSEcCtD
Cysteamine—SST—Signaling Pathways—ADAM17—liver cancer	0.000581	0.00276	CbGpPWpGaD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000573	0.00312	CcSEcCtD
Cysteamine—Discomfort—Doxorubicin—liver cancer	0.00057	0.0031	CcSEcCtD
Cysteamine—Anorexia—Epirubicin—liver cancer	0.00057	0.0031	CcSEcCtD
Cysteamine—Confusional state—Doxorubicin—liver cancer	0.000558	0.00303	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—ADAM17—liver cancer	0.000557	0.00265	CbGpPWpGaD
Cysteamine—Anaphylactic shock—Doxorubicin—liver cancer	0.000554	0.00301	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—IL6—liver cancer	0.000553	0.00263	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—F2—liver cancer	0.000547	0.0026	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PSMA4—liver cancer	0.000546	0.0026	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PSMD10—liver cancer	0.000546	0.0026	CbGpPWpGaD
Cysteamine—Nervous system disorder—Doxorubicin—liver cancer	0.000543	0.00295	CcSEcCtD
Cysteamine—Skin disorder—Doxorubicin—liver cancer	0.000538	0.00292	CcSEcCtD
Cysteamine—Somnolence—Epirubicin—liver cancer	0.000532	0.00289	CcSEcCtD
Cysteamine—Anorexia—Doxorubicin—liver cancer	0.000528	0.00287	CcSEcCtD
Cysteamine—Dyspepsia—Epirubicin—liver cancer	0.000527	0.00286	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—F2—liver cancer	0.000525	0.00249	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—PIK3CG—liver cancer	0.000524	0.00249	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PSMD10—liver cancer	0.000524	0.00249	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PSMA4—liver cancer	0.000524	0.00249	CbGpPWpGaD
Cysteamine—Decreased appetite—Epirubicin—liver cancer	0.00052	0.00283	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Epirubicin—liver cancer	0.000516	0.00281	CcSEcCtD
Cysteamine—Fatigue—Epirubicin—liver cancer	0.000516	0.0028	CcSEcCtD
Cysteamine—Constipation—Epirubicin—liver cancer	0.000512	0.00278	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—PIK3CG—liver cancer	0.000502	0.00239	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—F2—liver cancer	0.000497	0.00236	CbGpPWpGaD
Cysteamine—Feeling abnormal—Epirubicin—liver cancer	0.000493	0.00268	CcSEcCtD
Cysteamine—Somnolence—Doxorubicin—liver cancer	0.000492	0.00268	CcSEcCtD
Cysteamine—Gastrointestinal pain—Epirubicin—liver cancer	0.000489	0.00266	CcSEcCtD
Cysteamine—Dyspepsia—Doxorubicin—liver cancer	0.000487	0.00265	CcSEcCtD
Cysteamine—Decreased appetite—Doxorubicin—liver cancer	0.000481	0.00262	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000478	0.0026	CcSEcCtD
Cysteamine—Fatigue—Doxorubicin—liver cancer	0.000477	0.0026	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—F2—liver cancer	0.000477	0.00227	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—PIK3CG—liver cancer	0.000476	0.00226	CbGpPWpGaD
Cysteamine—Urticaria—Epirubicin—liver cancer	0.000475	0.00258	CcSEcCtD
Cysteamine—Constipation—Doxorubicin—liver cancer	0.000473	0.00257	CcSEcCtD
Cysteamine—Body temperature increased—Epirubicin—liver cancer	0.000473	0.00257	CcSEcCtD
Cysteamine—Abdominal pain—Epirubicin—liver cancer	0.000473	0.00257	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—PIK3CD—liver cancer	0.000461	0.00219	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—PIK3CG—liver cancer	0.000456	0.00217	CbGpPWpGaD
Cysteamine—Feeling abnormal—Doxorubicin—liver cancer	0.000456	0.00248	CcSEcCtD
Cysteamine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000453	0.00246	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—PIK3CD—liver cancer	0.000442	0.0021	CbGpPWpGaD
Cysteamine—Hypersensitivity—Epirubicin—liver cancer	0.000441	0.0024	CcSEcCtD
Cysteamine—Urticaria—Doxorubicin—liver cancer	0.00044	0.00239	CcSEcCtD
Cysteamine—Abdominal pain—Doxorubicin—liver cancer	0.000438	0.00238	CcSEcCtD
Cysteamine—Body temperature increased—Doxorubicin—liver cancer	0.000438	0.00238	CcSEcCtD
Cysteamine—Asthenia—Epirubicin—liver cancer	0.000429	0.00233	CcSEcCtD
Cysteamine—SST—Signaling Pathways—PRKCE—liver cancer	0.000423	0.00201	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—PIK3CD—liver cancer	0.000418	0.00199	CbGpPWpGaD
Cysteamine—Diarrhoea—Epirubicin—liver cancer	0.000409	0.00223	CcSEcCtD
Cysteamine—Hypersensitivity—Doxorubicin—liver cancer	0.000408	0.00222	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—PRKCE—liver cancer	0.000406	0.00193	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—PIK3CB—liver cancer	0.000401	0.00191	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—PIK3CD—liver cancer	0.000401	0.00191	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—IGF2—liver cancer	0.000401	0.00191	CbGpPWpGaD
Cysteamine—Asthenia—Doxorubicin—liver cancer	0.000397	0.00216	CcSEcCtD
Cysteamine—Dizziness—Epirubicin—liver cancer	0.000396	0.00215	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—PIK3CB—liver cancer	0.000385	0.00183	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—IGF2—liver cancer	0.000384	0.00183	CbGpPWpGaD
Cysteamine—Vomiting—Epirubicin—liver cancer	0.00038	0.00207	CcSEcCtD
Cysteamine—Diarrhoea—Doxorubicin—liver cancer	0.000379	0.00206	CcSEcCtD
Cysteamine—Rash—Epirubicin—liver cancer	0.000377	0.00205	CcSEcCtD
Cysteamine—Dermatitis—Epirubicin—liver cancer	0.000377	0.00205	CcSEcCtD
Cysteamine—Headache—Epirubicin—liver cancer	0.000375	0.00204	CcSEcCtD
Cysteamine—SST—Signaling Pathways—CSF2—liver cancer	0.000374	0.00178	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—RAF1—liver cancer	0.000373	0.00177	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—H2AFX—liver cancer	0.000369	0.00175	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—IL2—liver cancer	0.000369	0.00175	CbGpPWpGaD
Cysteamine—Dizziness—Doxorubicin—liver cancer	0.000366	0.00199	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—PIK3CB—liver cancer	0.000365	0.00173	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CSF2—liver cancer	0.000359	0.00171	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—RAF1—liver cancer	0.000358	0.0017	CbGpPWpGaD
Cysteamine—Nausea—Epirubicin—liver cancer	0.000355	0.00193	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—H2AFX—liver cancer	0.000354	0.00168	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—IL2—liver cancer	0.000353	0.00168	CbGpPWpGaD
Cysteamine—Vomiting—Doxorubicin—liver cancer	0.000352	0.00191	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—PIK3CB—liver cancer	0.00035	0.00166	CbGpPWpGaD
Cysteamine—Rash—Doxorubicin—liver cancer	0.000349	0.0019	CcSEcCtD
Cysteamine—Dermatitis—Doxorubicin—liver cancer	0.000349	0.0019	CcSEcCtD
Cysteamine—Headache—Doxorubicin—liver cancer	0.000347	0.00189	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—IL2—liver cancer	0.000335	0.00159	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TERT—liver cancer	0.000334	0.00159	CbGpPWpGaD
Cysteamine—Nausea—Doxorubicin—liver cancer	0.000329	0.00179	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—IL2—liver cancer	0.000321	0.00153	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TERT—liver cancer	0.00032	0.00152	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—KDR—liver cancer	0.000305	0.00145	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MAPK14—liver cancer	0.000303	0.00144	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—ESR1—liver cancer	0.000297	0.00141	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—F2—liver cancer	0.000294	0.0014	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—KDR—liver cancer	0.000293	0.00139	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MAPK14—liver cancer	0.000291	0.00138	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—ESR1—liver cancer	0.000285	0.00135	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—F2—liver cancer	0.000282	0.00134	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PIK3CG—liver cancer	0.000281	0.00134	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—APC—liver cancer	0.000281	0.00134	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—APC—liver cancer	0.000269	0.00128	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PIK3CG—liver cancer	0.000269	0.00128	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—BRAF—liver cancer	0.000264	0.00126	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—BRAF—liver cancer	0.000253	0.0012	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PIK3CD—liver cancer	0.000247	0.00117	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—PIK3CA—liver cancer	0.000245	0.00116	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—SERPINE1—liver cancer	0.000244	0.00116	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—KRAS—liver cancer	0.000242	0.00115	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PIK3CD—liver cancer	0.000237	0.00113	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—PIK3CA—liver cancer	0.000235	0.00112	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—SERPINE1—liver cancer	0.000234	0.00111	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—KRAS—liver cancer	0.000232	0.0011	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—PIK3CA—liver cancer	0.000222	0.00106	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—RAF1—liver cancer	0.000221	0.00105	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MTOR—liver cancer	0.000215	0.00102	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PIK3CB—liver cancer	0.000215	0.00102	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—PIK3CA—liver cancer	0.000213	0.00101	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—RAF1—liver cancer	0.000211	0.00101	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PIK3CB—liver cancer	0.000206	0.000981	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MTOR—liver cancer	0.000206	0.000981	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—HRAS—liver cancer	0.000206	0.000977	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CDKN1B—liver cancer	0.000202	0.000961	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—AKT1—liver cancer	0.0002	0.00095	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CASP3—liver cancer	0.000198	0.000942	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—IL2—liver cancer	0.000198	0.00094	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—HRAS—liver cancer	0.000197	0.000937	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—IL6—liver cancer	0.000197	0.000935	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CDKN1B—liver cancer	0.000194	0.000921	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CCND1—liver cancer	0.000193	0.000916	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—JUN—liver cancer	0.000192	0.000915	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—AKT1—liver cancer	0.000192	0.000911	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CTNNB1—liver cancer	0.000191	0.000908	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CASP3—liver cancer	0.00019	0.000903	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—IL2—liver cancer	0.00019	0.000901	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—IL6—liver cancer	0.000189	0.000897	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MMP9—liver cancer	0.000187	0.00089	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CDKN1A—liver cancer	0.000187	0.000887	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CCND1—liver cancer	0.000185	0.000879	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—JUN—liver cancer	0.000184	0.000877	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CTNNB1—liver cancer	0.000183	0.00087	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MAPK8—liver cancer	0.000182	0.000865	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—AKT1—liver cancer	0.000182	0.000863	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MMP9—liver cancer	0.000179	0.000853	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CDKN1A—liver cancer	0.000179	0.00085	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MAPK8—liver cancer	0.000175	0.00083	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—AKT1—liver cancer	0.000174	0.000827	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—VEGFA—liver cancer	0.000168	0.000799	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—STAT3—liver cancer	0.000166	0.000791	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—VEGFA—liver cancer	0.000161	0.000766	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—STAT3—liver cancer	0.00016	0.000758	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MYC—liver cancer	0.000155	0.000735	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TGFB1—liver cancer	0.000154	0.000733	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—MYC—liver cancer	0.000148	0.000705	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TGFB1—liver cancer	0.000148	0.000703	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—KRAS—liver cancer	0.000143	0.000679	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—KRAS—liver cancer	0.000137	0.000651	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PIK3CA—liver cancer	0.000131	0.000624	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TP53—liver cancer	0.000127	0.000604	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PIK3CA—liver cancer	0.000126	0.000598	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TP53—liver cancer	0.000122	0.000579	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—HRAS—liver cancer	0.000121	0.000577	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—HRAS—liver cancer	0.000116	0.000554	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—IL6—liver cancer	0.000116	0.000553	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—IL6—liver cancer	0.000111	0.00053	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—AKT1—liver cancer	0.000107	0.00051	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—AKT1—liver cancer	0.000103	0.000489	CbGpPWpGaD
